Logo - springer
Slogan - springer

Medicine - Radiology | EJNMMI Radiopharmacy and Chemistry

EJNMMI Radiopharmacy and Chemistry

EJNMMI Radiopharmacy and Chemistry

Editor-in-Chief: Philip H. Elsinga

ISSN: 2365-421X (electronic version)

Journal no. 41181

Learn more about the metrics of this journal PB_Banner_Open_Access_13317_ani_575x60
  • Focuses on research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes
  • Offers insight in novel concepts of imaging or radionuclide based therapeutic agent applications of relevance for the whole molecular imaging community
  • EANM sponsorship programme: The EANM Board decided to allocate funds to a dedicated Publication Fee Sponsorship Programme for EJNMMI Radiopharmacy and Chemistry. Through this programme the EANM will cover the charges that arise for selected articles.

EJNMMI Radiopharmacy and Chemistry is a peer-reviewed open access Journal and publishes new research in the field of development of new imaging and radionuclide based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight in novel concepts of imaging or radionuclide based therapeutic agent applications of relevance for the whole molecular imaging community. The journal reports original research articles, review papers, guidelines on application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in from of guidelines or position papers.

Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with the journals European Journal of Nuclear Medicine and Molecular Imaging, EJNMMI Physics, EJNMMI Research, and the European Journal of Hybrid Imaging.

Related subjects » Human Genetics - Inorganic Chemistry - Medicine - Radiology

Abstracted/Indexed in 

EMBASE, Google Scholar, CNKI, DOAJ, EBSCO Discovery Service, EBSCO TOC Premier, INIS Atomindex, OCLC WorldCat Discovery Service, ProQuest-ExLibris Primo, ProQuest-ExLibris Summon

Read this journal online

For authors and editors

  • Aims and Scope

    Aims and Scope

    Close

    EJNMMI Radiopharmacy and Chemistry publishes new research in the field of development of new imaging and radionuclide based therapeutic agents for application in nuclear medicine and molecular imaging. The journal provides a platform for chemists, pharmacists and basic scientists to present their views and scientific work. In addition, the journal provides insight in novel concepts of imaging or radionuclide based therapeutic agent applications of relevance for the whole molecular imaging community. The journal reports original research articles, review papers, guidelines on application of imaging or radionuclide therapy agents, editorials, and letters to the editor. Research articles on novel radiochemistry, new radiopharmaceuticals including their first biological evaluation, molecular imaging agents including optical imaging, MRI, and hybrid probes, are the main focus of the journal. To translate imaging and radionuclide therapy agents to the clinic, legislative issues related to their production and safety can be presented as well in from of guidelines or position papers.

  • Submit Online
  • Instructions for Authors

Alerts for this journal

 

Get the table of contents of every new issue published in EJNMMI Radiopharmacy and Chemistry.